{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:44:25Z","timestamp":1789764265924,"version":"4.0.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002243","name":"National Ataxia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["U01-NS106670"],"award-info":[{"award-number":["U01-NS106670"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01-NS122751"],"award-info":[{"award-number":["R01-NS122751"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ymthe.2024.02.033","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T11:41:17Z","timestamp":1709206877000},"page":"1359-1372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice"],"prefix":"10.1016","volume":"32","author":[{"given":"Kristen H.","family":"Schuster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie J.","family":"Zalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M.","family":"DiFranco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra F.","family":"Putka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas R.","family":"Stec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina I.","family":"Jarrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsal","family":"Naeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanrui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanfang","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4279-2758","authenticated-orcid":false,"given":"Hayley S.","family":"McLoughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.02.033_bib1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.pneurobio.2011.11.006","article-title":"Toward understanding Machado-Joseph disease","volume":"97","author":"Costa","year":"2012","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ymthe.2024.02.033_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-012-1000-x","article-title":"Brain pathology of spinocerebellar ataxias","volume":"124","author":"Seidel","year":"2012","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ymthe.2024.02.033_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pneurobio.2013.01.001","article-title":"Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7","volume":"104","author":"R\u00fcb","year":"2013","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ymthe.2024.02.033_bib4","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrn.2017.92","article-title":"Polyglutamine spinocerebellar ataxias - from genes to potential treatments","volume":"18","author":"Paulson","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ymthe.2024.02.033_bib5","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S1474-4422(10)70183-6","article-title":"Autosomal dominant cerebellar ataxias: Polyglutamine expansions and beyond","volume":"9","author":"Durr","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2024.02.033_bib6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaneurol.2019.0423","article-title":"Prevalence of Carriers of Intermediate and Pathological Polyglutamine Disease-Associated Alleles Among Large Population-Based Cohorts","volume":"76","author":"Gardiner","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2024.02.033_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104635","article-title":"Pathogenesis of SCA3 and implications for other polyglutamine diseases","volume":"134","author":"McLoughlin","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2024.02.033_bib8","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.bbrc.2007.08.062","article-title":"Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination","volume":"362","author":"Schmitt","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2024.02.033_bib9","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.omtn.2017.04.005","article-title":"Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models","volume":"7","author":"Moore","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2024.02.033_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2019.101504","article-title":"Antisense oligonucleotide therapy rescues aggresome formation in a novel spinocerebellar ataxia type 3 human embryonic stem cell line","volume":"39","author":"Moore","year":"2019","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.ymthe.2024.02.033_bib11","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s12192-012-0346-2","article-title":"Basal and stress-induced Hsp70 are modulated by ataxin-3","volume":"17","author":"Reina","year":"2012","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.ymthe.2024.02.033_bib12","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2024.02.033_bib13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ymthe.2024.02.033_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/jps.10473","article-title":"Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys","volume":"93","author":"Yu","year":"2004","journal-title":"J.\u00a0Pharm. Sci."},{"key":"10.1016\/j.ymthe.2024.02.033_bib15","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2024.02.033_bib16","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.02.033_bib17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12311-020-01179-7","article-title":"Antisense Oligonucleotide Therapy Targeted Against ATXN3 Improves Potassium Channel-Mediated Purkinje Neuron Dysfunction in Spinocerebellar Ataxia Type 3","volume":"20","author":"Bushart","year":"2020","journal-title":"Cerebellum"},{"key":"10.1016\/j.ymthe.2024.02.033_bib18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/ana.25264","article-title":"Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice","volume":"84","author":"McLoughlin","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2024.02.033_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/srep35200","article-title":"Antisense oligonucleotide-mediated exon skipping as a strategy to reduce proteolytic cleavage of ataxin-3","volume":"6","author":"Toonen","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2024.02.033_bib20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.omtn.2017.06.019","article-title":"Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice","volume":"8","author":"Toonen","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2024.02.033_bib21","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/ana.26713","article-title":"ASO silencing reverses abnormal neurochemistry in spinocerebellar ataxia 3 mice","volume":"94","author":"McLoughlin","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2024.02.033_bib22","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1523\/JNEUROSCI.1954-20.2021","article-title":"Impaired oligodendrocyte maturation is an early feature in SCA3 disease pathogenesis","volume":"42","author":"Schuster","year":"2022","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2024.02.033_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1118429","article-title":"Disease-associated oligodendrocyte signatures are spatiotemporally dysregulated in spinocerebellar ataxia type 3","volume":"17","author":"Schuster","year":"2023","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ymthe.2024.02.033_bib24","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/mds.28140","article-title":"In\u00a0Vivo Molecular Signatures of Cerebellar Pathology in Spinocerebellar Ataxia Type 3","volume":"35","author":"Costa","year":"2020","journal-title":"Mov Disord."},{"key":"10.1016\/j.ymthe.2024.02.033_bib25","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41586-020-2494-3","article-title":"Suppression of proteolipid protein rescues Pelizaeus-Merzbacher disease","volume":"585","author":"Elitt","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.02.033_bib26","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/nar\/gkaa1235","article-title":"The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration","volume":"49","author":"Jafar-Nejad","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2024.02.033_bib27","doi-asserted-by":"crossref","first-page":"7109","DOI":"10.1093\/nar\/gkad371","article-title":"A single-cell map of antisense oligonucleotide activity in the brain","volume":"51","author":"Mortberg","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2024.02.033_bib28","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/s41593-022-01104-7","article-title":"A shared disease-associated oligodendrocyte signature among multiple CNS pathologies","volume":"25","author":"Kenigsbuch","year":"2022","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymthe.2024.02.033_bib29","doi-asserted-by":"crossref","first-page":"9622","DOI":"10.1073\/pnas.1818042116","article-title":"Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease","volume":"116","author":"Ferrari Bardile","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.02.033_bib30","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/brain\/aws339","article-title":"Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis","volume":"136","author":"Philips","year":"2013","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2024.02.033_bib31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/mds.28393","article-title":"Oligodendrocytes, a New Player in the Etiology of Parkinson's Disease","volume":"36","author":"Errea","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2024.02.033_bib32","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3390\/cells12040601","article-title":"Myelinating Glia: Potential Therapeutic Targets in Polyglutamine Spinocerebellar Ataxias","volume":"12","author":"Putka","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2024.02.033_bib33","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.neuron.2023.10.039","article-title":"Longitudinal single-cell transcriptional dynamics throughout neurodegeneration in SCA1","volume":"112","author":"Tejwani","year":"2024","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2024.02.033_bib34","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.neuron.2018.12.020","article-title":"Oligodendrocyte Progenitor Cells Become Regionally Diverse and Heterogeneous with Age","volume":"101","author":"Spitzer","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2024.02.033_bib35","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.3390\/cells11162615","article-title":"Pathogenetic Mechanisms Underlying Spinocerebellar Ataxia Type 3 Are Altered in Primary Oligodendrocyte Culture","volume":"11","author":"Schuster","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2024.02.033_bib36","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1038\/mt.2013.144","article-title":"Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease","volume":"21","author":"Costa","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.02.033_bib37","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/hmg\/11.9.1075","article-title":"YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit","volume":"11","author":"Cemal","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2024.02.033_bib38","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature02033","article-title":"A gene expression atlas of the central nervous system based on bacterial artificial chromosomes","volume":"425","author":"Gong","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.02.033_bib39","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/nn1426","article-title":"High cholesterol level is essential for myelin membrane growth","volume":"8","author":"Saher","year":"2005","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymthe.2024.02.033_bib40","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.bbalip.2015.02.010","article-title":"Cholesterol in myelin biogenesis and hypomyelinating disorders","volume":"1851","author":"Saher","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymthe.2024.02.033_bib41","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00234-020-02528-3","article-title":"Corticospinal tract involvement in spinocerebellar ataxia type 3: a diffusion tensor imaging study","volume":"63","author":"Inada","year":"2021","journal-title":"Neuroradiology"},{"key":"10.1016\/j.ymthe.2024.02.033_bib42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1089\/108729002761381320","article-title":"Trafficking of intracerebroventricularly injected antisense oligonucleotides in the mouse brain","volume":"12","author":"Chauhan","year":"2002","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"10.1016\/j.ymthe.2024.02.033_bib43","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1089\/nat.2016.0642","article-title":"Distribution and Penetration of Intracerebroventricularly Administered 2'OMePS Oligonucleotide in the Mouse Brain","volume":"27","author":"Casaca-Carreira","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2024.02.033_bib44","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/brain\/awz328","article-title":"Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders","volume":"143","author":"Silva","year":"2020","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2024.02.033_bib45","series-title":"Basic Neurochemistry: Molecular, Cellular, and Medical Aspects","article-title":"Characteristic Composition of Myelin","author":"Morell","year":"1999"},{"key":"10.1016\/j.ymthe.2024.02.033_bib46","series-title":"Cholesterol: Its Functions and Metabolism in Biology and Medicine","first-page":"173","article-title":"Cholesterol and myelin","author":"Snipes","year":"1997"},{"key":"10.1016\/j.ymthe.2024.02.033_bib47","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3390\/cells11071223","article-title":"Drosophila as a Model of Unconventional Translation in Spinocerebellar Ataxia Type 3","volume":"11","author":"Johnson","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2024.02.033_bib48","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ana.25297","article-title":"Structural signature of SCA3: From presymptomatic to late disease stages","volume":"84","author":"Rezende","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2024.02.033_bib49","series-title":"Polyglutamine Disorders","first-page":"233","article-title":"The Neuropathology of Spinocerebellar Ataxia Type 3\/Machado-Joseph Disease","author":"Koeppen","year":"2018"},{"key":"10.1016\/j.ymthe.2024.02.033_bib50","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s12311-014-0619-7","article-title":"Spinal cord damage in Machado-Joseph disease","volume":"14","author":"Fahl","year":"2015","journal-title":"Cerebellum"},{"key":"10.1016\/j.ymthe.2024.02.033_bib51","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.4103\/1673-5374.368302","article-title":"Disease-associated oligodendrocyte signatures in neurodegenerative disease: the known and unknown","volume":"18","author":"Schuster","year":"2023","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.ymthe.2024.02.033_bib52","article-title":"Intracerebroventricular viral injection of the neonatal mouse brain for persistent and widespread neuronal transduction","volume":"15","author":"Kim","year":"2014","journal-title":"J.\u00a0Vis. Exp."},{"key":"10.1016\/j.ymthe.2024.02.033_bib53","article-title":"Direct intraventricular delivery of drugs to the rodent central nervous system","volume":"12","author":"DeVos","year":"2013","journal-title":"J.\u00a0Vis. Exp."},{"key":"10.1016\/j.ymthe.2024.02.033_bib54","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/1471-2105-9-482","article-title":"CellProfiler Analyst: data exploration and analysis software for complex image-based screens","volume":"9","author":"Jones","year":"2008","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.ymthe.2024.02.033_bib55","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0558-20.2021","article-title":"MyelTracer: A Semi-Automated Software for Myelin g-Ratio Quantification","volume":"8","author":"Kaiser","year":"2021","journal-title":"eNeuro"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624001023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624001023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T09:20:06Z","timestamp":1746091206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624001023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1525001624001023"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.02.033","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.07.18.500473","asserted-by":"object"}]},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.02.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}